What are the specific requirements for medical insurance reimbursement of Vemurafenib?

Vemurafenib/zobovo(Vemurafenib), as an anti-cancer drug targeting BRAF mutations, is a milestone in the treatment of melanoma. Since the original research drug Zelboraf (Zelboraf) was launched in China, it has quickly entered the national medical insurance directory due to its advantages of strong pertinence and clear efficacy. For many patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, this will undoubtedly greatly reduce the financial pressure and improve drug accessibility.

The focus of the medical insurance policy is to accurately locate the applicable population. Only patients confirmed by formal genetic testing to carry theBRAF V600 mutation are eligible for reimbursement. This is because vemurafenib blocks the MAPK signaling pathway by inhibiting the activity of the mutant BRAF protein. Without the mutation, the drug will lose its intended effect. The medical insurance catalog clearly stipulates that its coverage is limited to patients with melanoma that is unresectable or has distant metastasis. Early-stage cases that can be cured through surgery are not covered by reimbursement.

Patients must complete the BRAF V600 mutation test at a qualified hospital. The prescription and medication follow-up will be carried out by experienced doctors. This series of steps is an important condition for medical insurance reimbursement to ensure the rationality and standardization of drug use. There may be differences in specific reimbursement ratios and payment policies in some regions, but the overall direction is uniformly promoted by the National Medical Insurance Administration to benefit more patients.

Medical insurance coverage is not only a kind of economic security, but also conveys the importance of precision cancer treatment at the policy level. In the past, many patients gave up treatment because of the high price of targeted drugs. However, now that medical insurance has been included, the use of vemurafenib has increased significantly, which not only prolongs patient survival, but also improves the overall quality of treatment. With the continuous enrichment of targeted drugs, the medical insurance catalog will gradually expand, forming a more systematic precision medical security network.

Reference: https://www.drugs.com/mtm/vemurafenib.html